Knocking down barriers: advances in siRNA delivery (vol 8, pg 129, 2009)

Nature Reviews Drug Discovery 8, 129–138 (2009) | 10.1038/nrd2742 On page 136 in Table 3, the clinical trial for acute renal failure has been attributed to Quark/Pfizer when it should be attributed to Quark alone. In addition, the authors would like to clarify that, following a Phase I/II trial in patients with wet age-related macular degeneration, the siRNA drug candidate PF-4523655 (RTP801i-14) is now being studied in a Phase II trial for diabetic macular oedema conducted by Pfizer in collaboration with Quark.